prva-20210930
0001759655false12-31Q32021001100017596552021-01-012021-09-30xbrli:shares00017596552021-11-02iso4217:USD00017596552021-09-3000017596552020-12-31iso4217:USDxbrli:shares00017596552021-07-012021-09-3000017596552020-07-012020-09-3000017596552020-01-012020-09-300001759655us-gaap:CommonStockMember2019-12-310001759655us-gaap:AdditionalPaidInCapitalMember2019-12-310001759655us-gaap:RetainedEarningsMember2019-12-310001759655us-gaap:ParentMember2019-12-310001759655us-gaap:NoncontrollingInterestMember2019-12-3100017596552019-12-310001759655us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001759655us-gaap:ParentMember2020-01-012020-03-3100017596552020-01-012020-03-310001759655us-gaap:RetainedEarningsMember2020-01-012020-03-310001759655us-gaap:NoncontrollingInterestMember2020-01-012020-03-310001759655us-gaap:CommonStockMember2020-03-310001759655us-gaap:AdditionalPaidInCapitalMember2020-03-310001759655us-gaap:RetainedEarningsMember2020-03-310001759655us-gaap:ParentMember2020-03-310001759655us-gaap:NoncontrollingInterestMember2020-03-3100017596552020-03-310001759655us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001759655us-gaap:ParentMember2020-04-012020-06-3000017596552020-04-012020-06-300001759655us-gaap:RetainedEarningsMember2020-04-012020-06-300001759655us-gaap:NoncontrollingInterestMember2020-04-012020-06-300001759655us-gaap:CommonStockMember2020-06-300001759655us-gaap:AdditionalPaidInCapitalMember2020-06-300001759655us-gaap:RetainedEarningsMember2020-06-300001759655us-gaap:ParentMember2020-06-300001759655us-gaap:NoncontrollingInterestMember2020-06-3000017596552020-06-300001759655us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001759655us-gaap:ParentMember2020-07-012020-09-300001759655us-gaap:CommonStockMember2020-07-012020-09-300001759655us-gaap:RetainedEarningsMember2020-07-012020-09-300001759655us-gaap:NoncontrollingInterestMember2020-07-012020-09-300001759655us-gaap:CommonStockMember2020-09-300001759655us-gaap:AdditionalPaidInCapitalMember2020-09-300001759655us-gaap:RetainedEarningsMember2020-09-300001759655us-gaap:ParentMember2020-09-300001759655us-gaap:NoncontrollingInterestMember2020-09-3000017596552020-09-300001759655us-gaap:CommonStockMember2020-12-310001759655us-gaap:AdditionalPaidInCapitalMember2020-12-310001759655us-gaap:RetainedEarningsMember2020-12-310001759655us-gaap:ParentMember2020-12-310001759655us-gaap:NoncontrollingInterestMember2020-12-310001759655us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001759655us-gaap:ParentMember2021-01-012021-03-3100017596552021-01-012021-03-310001759655us-gaap:RetainedEarningsMember2021-01-012021-03-310001759655us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001759655us-gaap:CommonStockMember2021-03-310001759655us-gaap:AdditionalPaidInCapitalMember2021-03-310001759655us-gaap:RetainedEarningsMember2021-03-310001759655us-gaap:ParentMember2021-03-310001759655us-gaap:NoncontrollingInterestMember2021-03-3100017596552021-03-310001759655us-gaap:CommonStockMember2021-04-012021-06-300001759655us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001759655us-gaap:ParentMember2021-04-012021-06-3000017596552021-04-012021-06-300001759655us-gaap:RetainedEarningsMember2021-04-012021-06-300001759655us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001759655us-gaap:CommonStockMember2021-06-300001759655us-gaap:AdditionalPaidInCapitalMember2021-06-300001759655us-gaap:RetainedEarningsMember2021-06-300001759655us-gaap:ParentMember2021-06-300001759655us-gaap:NoncontrollingInterestMember2021-06-3000017596552021-06-300001759655us-gaap:CommonStockMember2021-07-012021-09-300001759655us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001759655us-gaap:ParentMember2021-07-012021-09-300001759655us-gaap:RetainedEarningsMember2021-07-012021-09-300001759655us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001759655us-gaap:CommonStockMember2021-09-300001759655us-gaap:AdditionalPaidInCapitalMember2021-09-300001759655us-gaap:RetainedEarningsMember2021-09-300001759655us-gaap:ParentMember2021-09-300001759655us-gaap:NoncontrollingInterestMember2021-09-30prva:market00017596552021-09-302021-09-30xbrli:pureprva:company0001759655us-gaap:IPOMember2021-05-032021-05-030001759655us-gaap:IPOMember2021-05-030001759655us-gaap:PrivatePlacementMember2021-05-032021-05-030001759655prva:InitialPublicOfferingAndPrivatePlacementMember2021-05-032021-05-03prva:segment0001759655us-gaap:AccountingStandardsUpdate201602Member2021-01-010001759655prva:FFSPatientCareMember2021-07-012021-09-300001759655prva:FFSPatientCareMember2020-07-012020-09-300001759655prva:FFSPatientCareMember2021-01-012021-09-300001759655prva:FFSPatientCareMember2020-01-012020-09-300001759655prva:FFSAdministrativeServicesMember2021-07-012021-09-300001759655prva:FFSAdministrativeServicesMember2020-07-012020-09-300001759655prva:FFSAdministrativeServicesMember2021-01-012021-09-300001759655prva:FFSAdministrativeServicesMember2020-01-012020-09-300001759655prva:SharedSavingsMember2021-07-012021-09-300001759655prva:SharedSavingsMember2020-07-012020-09-300001759655prva:SharedSavingsMember2021-01-012021-09-300001759655prva:SharedSavingsMember2020-01-012020-09-300001759655prva:CareManagementFeePMPMMember2021-07-012021-09-300001759655prva:CareManagementFeePMPMMember2020-07-012020-09-300001759655prva:CareManagementFeePMPMMember2021-01-012021-09-300001759655prva:CareManagementFeePMPMMember2020-01-012020-09-300001759655prva:OtherRevenueMember2021-07-012021-09-300001759655prva:OtherRevenueMember2020-07-012020-09-300001759655prva:OtherRevenueMember2021-01-012021-09-300001759655prva:OtherRevenueMember2020-01-012020-09-300001759655prva:CommercialInsurersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012021-09-300001759655prva:CommercialInsurersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2020-07-012020-09-300001759655prva:CommercialInsurersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001759655prva:CommercialInsurersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-09-300001759655prva:GovernmentPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001759655prva:GovernmentPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001759655prva:GovernmentPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001759655prva:GovernmentPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberprva:PatientMember2021-07-012021-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberprva:PatientMember2020-07-012020-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberprva:PatientMember2021-01-012021-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberprva:PatientMember2020-01-012020-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001759655us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001759655us-gaap:TradeNamesMember2021-09-300001759655us-gaap:TradeNamesMember2020-12-310001759655us-gaap:CustomerRelationshipsMember2021-09-300001759655us-gaap:CustomerRelationshipsMember2020-12-310001759655us-gaap:CustomerListsMember2021-09-300001759655us-gaap:CustomerListsMember2020-12-310001759655us-gaap:ServiceAgreementsMember2021-09-300001759655us-gaap:ServiceAgreementsMember2020-12-310001759655srt:MinimumMemberus-gaap:BuildingMember2021-09-300001759655srt:MaximumMemberus-gaap:BuildingMember2021-09-300001759655us-gaap:FurnitureAndFixturesMember2021-09-300001759655us-gaap:FurnitureAndFixturesMember2020-12-310001759655us-gaap:ComputerEquipmentMember2021-09-300001759655us-gaap:ComputerEquipmentMember2020-12-310001759655us-gaap:LeaseholdImprovementsMember2021-09-300001759655us-gaap:LeaseholdImprovementsMember2020-12-310001759655us-gaap:SecuredDebtMember2021-09-300001759655us-gaap:SecuredDebtMember2020-12-310001759655us-gaap:SecuredDebtMember2019-11-150001759655us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:SecuredDebtMember2019-11-152019-11-150001759655us-gaap:SecuredDebtMemberus-gaap:BaseRateMember2019-11-152019-11-150001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-11-150001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-07-170001759655us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2019-11-150001759655us-gaap:BridgeLoanMemberus-gaap:LineOfCreditMember2019-11-150001759655us-gaap:SecuredDebtMember2019-11-152019-11-150001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-08-270001759655us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2021-08-270001759655us-gaap:LineOfCreditMemberus-gaap:EurodollarMember2021-08-272021-08-270001759655us-gaap:LineOfCreditMemberus-gaap:BaseRateMember2021-08-272021-08-270001759655prva:DebtInstrumentCovenantPeriodOneMemberus-gaap:SecuredDebtMember2021-08-272021-08-270001759655prva:DebtInstrumentCovenantPeriodTwoMemberus-gaap:SecuredDebtMember2021-08-272021-08-270001759655us-gaap:SecuredDebtMember2021-08-272021-08-270001759655us-gaap:LineOfCreditMember2021-08-272021-08-270001759655us-gaap:LineOfCreditMember2021-08-270001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-03-012020-03-310001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMember2021-01-012021-09-300001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2021-01-012021-09-300001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-07-012020-07-310001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-012020-09-300001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-08-290001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-08-310001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-09-300001759655us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-12-3100017596552021-05-030001759655prva:AffiliateOfAnthemIncInvestorMembersrt:AffiliatedEntityMember2021-05-030001759655us-gaap:EmployeeStockOptionMember2014-01-170001759655us-gaap:EmployeeStockOptionMember2018-08-280001759655us-gaap:EmployeeStockOptionMember2021-04-012021-04-010001759655us-gaap:ShareBasedCompensationAwardTrancheOneMember2021-04-012021-04-010001759655us-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-04-012021-04-010001759655us-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-04-012021-04-010001759655srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2021-04-012021-04-010001759655srt:ChiefExecutiveOfficerMember2021-04-012021-04-010001759655us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001759655srt:ScenarioForecastMemberus-gaap:EmployeeStockOptionMember2021-10-012023-03-310001759655prva:OmnibusIncentivePlanMember2021-04-060001759655prva:OmnibusIncentivePlanMember2021-04-062021-04-060001759655us-gaap:RestrictedStockUnitsRSUMemberprva:OmnibusIncentivePlanMember2021-04-062021-04-0600017596552021-04-0600017596552021-04-062021-04-060001759655prva:EmployeeStockPurchasePlanMember2021-04-012021-04-300001759655prva:EmployeeStockPurchasePlanMember2021-04-3000017596552020-12-312020-12-310001759655us-gaap:RestrictedStockUnitsRSUMember2020-12-310001759655us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001759655us-gaap:RestrictedStockUnitsRSUMember2021-09-300001759655prva:CostOfPlatformMember2021-07-012021-09-300001759655prva:CostOfPlatformMember2020-07-012020-09-300001759655prva:CostOfPlatformMember2021-01-012021-09-300001759655prva:CostOfPlatformMember2020-01-012020-09-300001759655us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001759655us-gaap:SellingAndMarketingExpenseMember2020-07-012020-09-300001759655us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001759655us-gaap:SellingAndMarketingExpenseMember2020-01-012020-09-300001759655us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001759655us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001759655us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001759655us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001759655srt:AffiliatedEntityMember2020-10-310001759655srt:AffiliatedEntityMember2020-10-312020-10-310001759655srt:AffiliatedEntityMemberprva:InterestPaidOnRelatedPartyDebtMember2020-01-012020-10-310001759655srt:AffiliatedEntityMember2020-12-22prva:institution0001759655prva:SixPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001759655prva:SixPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001759655prva:SixPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001759655prva:SixPayersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001759655prva:SixPayersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-09-302021-09-300001759655prva:SixPayersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-12-312020-12-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 10-Q
_______________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from      to
Commission file number 001-40365
_________________________
Privia Health Group, Inc.
(Exact Name of Registrant as Specified in Its Charter)
_________________________
Delaware
81-3599420
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
950 N. Glebe Rd.,
Suite 700
Arlington,Virginia22203
(Address of Principal Executive Offices)
(Zip Code)
(571) 366-8850
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☐    No  ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer¨
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒
As of November 2, 2021 the registrant had outstanding 106,498,546 shares of common stock.


Table of Contents
TABLE OF CONTENTS
Page


Table of Contents
INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include factors related to, among other things:
the heavily regulated industry in which we operate, and if we fail to comply with applicable healthcare laws and government regulations, we could incur financial penalties and become excluded from participating in government health care programs;
our dependence on relationships with Medical Groups (defined herein), some of which we do not own;
our growth strategy, which may not prove viable and we may not realize expected results;
difficulties implementing our proprietary end-to-end, cloud-based technology solution (the “Privia Technology Solution”) for Privia Physicians (defined herein) and new Medical Groups;
the high level of competition in our industry and our failure to compete and innovate;
challenges in successfully establishing a presence in new geographic markets;
our reliance on our electronic medical record (“EMR”) vendor, athenahealth, Inc., which the Privia Technology Solution is integrated and built upon;
changes in the payer mix of patients and potential decreases in our reimbursement rates as a result of consolidation among commercial payers;
our use, disclosure, and other processing of personally identifiable information, including health information, is subject to the Health Insurance Portability and Accountability Act of 1996 and other federal and state privacy and security regulations; and
those factors referenced in Part II, Item 1A, “Risk Factors” in the Company’s final prospectus dated April 28, 2021, filed with the Securities and Exchange Commission (“SEC”) on April 30, 2021 (the “Prospectus”) and our other public filings.

You should read this quarterly report on Form 10-Q and the documents that we reference in this quarterly report on Form 10-Q and have filed as exhibits to this quarterly report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this quarterly report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this quarterly report on Form 10-Q, whether as a result of any new information, future events or otherwise.

1

Table of Contents
Part I - Financial Information
ITEM 1. FINANCIAL STATEMENTS
Privia Health Group, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
September 30, 2021December 31, 2020
Assets(unaudited)
Current assets:
Cash and cash equivalents$362,112 $84,633 
Accounts receivable98,384 99,118 
Prepaid expenses and other current assets8,928 6,333 
Total current assets469,424 190,084 
Non-current assets:
Property and equipment, net4,341 4,814 
Right-of-use asset5,377  
Intangible assets, net5,498 5,980 
Goodwill118,663 118,663 
Deferred tax asset25,374 4,953 
Other non-current assets3,384 4,475 
Total non-current assets162,637 138,885 
Total assets$632,061 $328,969 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$3,266 $5,235 
Accrued expenses31,303 31,185 
Physician and practice liability144,996 106,811 
Current portion of note payable875 875 
Operating lease liabilities, current2,200  
Other current liabilities4,602 2,832 
Total current liabilities187,242 146,938 
Non-current liabilities:
Note payable, net of current portion31,664 32,784 
Operating lease liabilities, non-current7,827  
Other non-current liabilities333 5,595 
Total non-current liabilities39,824 38,379 
Total liabilities227,066 185,317 
Commitments and contingencies (Note 11)
Stockholders’ equity:
Common stock, $0.01 par value, 1,000,000,000 and 150,000,000 shares authorized; 106,234,792 and 95,985,817 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
1,062 960 
Additional paid-in capital605,667 165,666 
Accumulated deficit(196,129)(19,878)
Total Privia Health Group, Inc. stockholders’ equity410,600 146,748 
Non-controlling interest(5,605)(3,096)
Total stockholders’ equity404,995 143,652 
Total liabilities and stockholders’ equity$632,061 $328,969 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

Table of Contents
Privia Health Group, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2021202020212020
Revenue$251,524 $207,170 $690,887 $603,376 
Operating expenses:
Physician and practice expense190,055 160,432 521,105 467,059 
Cost of platform35,314 25,241 131,007 77,133 
Sales and marketing4,588 2,709 18,950 7,381 
General and administrative33,910 9,788 216,563 29,196 
Depreciation and amortization466 457 1,351 1,389 
Total operating expenses264,333 198,627 888,976 582,158 
Operating (loss) income(12,809)8,543 (198,089)21,218 
Interest expense292 504 885 1,480 
(Loss) income before benefit from income taxes(13,101)8,039 (198,974)19,738 
Benefit from income taxes(2,210)(8,561)(20,214)(7,387)
Net (loss) income(10,891)16,600 (178,760)27,125 
Less: Loss attributable to non-controlling interests(1,776)(85)(2,509)(255)
Net (loss) income attributable to Privia Health Group, Inc. $(9,115)$16,685 $(176,251)$27,380 
Net (loss) income per share attributable to Privia Health Group, Inc. stockholders – basic and diluted$(0.09)$0.17 $(1.74)$0.29 
Weighted average common shares outstanding – basic and diluted105,896,622 95,950,929 101,576,775 95,945,804 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

Table of Contents
Privia Health Group, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(unaudited)
(in thousands except share amounts)
Common Stock SharesCommon StockAdditional Paid-in CapitalAccumulated DeficitTotal Stockholders’ Equity attributable to Privia Health Group, Inc.Non-controlling InterestTotal Stockholders’ Equity
Balance at December 31, 201995,931,549 $959 $160,375 $(51,122)$110,212 $(2,756)$107,456 
Stock-based compensation expense— — 121 — 121 — 121 
Net income— — — 5,414 5,414 (85)5,329 
Balance at March 31, 202095,931,549 $959 $160,496 $(45,708)$115,747 $(2,841)$112,906 
Stock-based compensation expense— — 121 — 121 121 
Net income— — 5,281 5,281 (85)5,196 
Balance at June 30, 202095,931,549 $959 $160,617 $(40,427)$121,149 $(2,926)$118,223 
Stock-based compensation expense— — 121 — 121 — 121 
Stock option exercised54,268 1 107 — 108 — 108 
Net income— — — 16,685 16,685 (85)16,600 
Balance at September 30, 202095,985,817 $960 $160,845 $(23,742)$138,063 $(3,011)$135,052 
Balance at December 31, 202095,985,817 $960 $165,666 $(19,878)$146,748 $(3,096)$143,652 
Stock-based compensation expense— — 101 — 101 — 101 
Net income — — — 5,398 5,398 218 5,616 
Balance at March 31, 202195,985,817 $960 $165,767 $(14,480)$152,247 $(2,878)$149,369 
Issuance of common stock upon closing of initial public offering9,725,000 97 210,897 — 210,994 — 210,994 
Issuance of common stock upon exercise of stock options and vesting of restricted stock units
29,645 — 33 — 33 — 33 
Stock-based compensation expense— — 202,560 — 202,560 — 202,560 
Net loss— — — (172,534)(172,534)(951)(173,485)
Balance at June 30, 2021105,740,462 $1,057 $579,257 $(187,014)$393,300 $(3,829)$389,471 
Issuance of common stock upon exercise of stock options and vesting of restricted stock units
494,330 5 610 — 615 — 615 
Stock-based compensation expense— — 25,800 — 25,800 — 25,800 
Net loss— — — (9,115)(9,115)(1,776)(10,891)
Balance at September 30, 2021106,234,792 $1,062 $605,667 $(196,129)$410,600 $(5,605)$404,995 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

Table of Contents
Privia Health Group, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
For the Nine Months Ended September 30,
20212020
Cash flows from operating activities
Net (loss) income$(178,760)$27,125 
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation 869 895 
Amortization of intangibles482 483 
Amortization of debt issuance costs120 100 
Stock-based compensation228,461 363 
Deferred tax benefit(20,421)(7,770)
Changes in asset and liabilities:
Accounts receivable734 (10,138)
Prepaid expenses and other current assets(7,972)(1,570)
Other non-current assets1,091 2,242 
Accounts payable(2,064)2,459 
Accrued expenses118 (4,061)
Physician and practice liability38,185 30,883 
Other current liabilities1,770 815 
Operating lease liabilities10,027  
Other long-term liabilities(5,262)404 
Net cash provided by in operating activities67,378 42,230 
Cash from investing activities
Purchases of property and equipment(396)(380)
Net cash used in investing activities(396)(380)
Cash flows from financing activities
Proceeds from initial public offering223,686  
Payments of underwriting fees, net of discounts and offering costs(12,691) 
Repayment of note payable (656)(656)
Proceeds from exercised stock options648 108 
Debt issuance costs(490) 
Proceeds from revolving loan 10,000 
Line of credit payments (10,000)
Net cash provided by (used in) financing activities210,497 (548)
Net increase in cash and cash equivalents277,479 41,302 
Cash and cash equivalents at beginning of period84,633 46,889 
Cash and cash equivalents at end of period$362,112 $88,191 
Supplemental disclosure of cash flow information:
Interest paid$855 $1,599 
Income taxes paid$451 $371 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Table of Contents
Privia Health Group, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
1.Organization and Summary of Significant Accounting Policies
Organization
Privia Health Group, Inc. (NASDAQ: PRVA) (“we”, “our” the “Company”), became the sole shareholder of PH Group Holdings Corp. (“PH Holdings”) (formerly Brighton Health Services Holding Corporation) effective August 11, 2016. At the time, the Company was a wholly owned subsidiary of Brighton Health Group Holdings, LLC (“BHG Holdings”) (formerly MC Acquisition Holdings I, LLC, HoldCo).
The Company uses the same operational and financial model in each market. As of September 30, 2021, Privia operates in six markets: 1) the Mid-Atlantic Region (states of Virginia, Maryland and the District of Columbia); 2) the state of Georgia; 3) the Gulf Coast Region (Houston, Texas); 4) North Texas (Dallas/Fort Worth, Texas); 5) Central Florida and 6) the state of Tennessee.
Medical groups are formed in each market with the primary purpose to operate as a physician group practice with healthcare services being furnished through physician members (“Privia Physicians”) and non-physician clinicians (together, “Privia Providers”) supervised by Privia Physicians.
The Company also forms local management companies to provide administrative and management services (“MSOs”) to the medical groups through a Management Services Agreement (“MSA”) in each market. The Company owns 100% of all MSOs, except two where the Company is at least the majority owner.
Initial Public Offering
On May 3, 2021, the Company closed its initial public offering (“IPO”) of 22,425,000 shares of the Company’s common stock, $0.01 par value per share, at an offering price of $23.00 per share. On May 3, 2021, the Company also sold 4,000,000 shares to an affiliate of Anthem, Inc. (“Anthem”) in a private placement. In aggregate, the shares issued in the offering and Anthem private placement generated gross proceeds of $223.7 million and $211.0 million in net proceeds, which is net of underwriters’ discounts and commissions, and other offering costs.
Basis of Presentation
The condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its subsidiaries. Amounts shown on the condensed consolidated statements of operations within the operating expense categories of physician and practice expense, cost of platform, selling and marketing, and general and administrative are recorded exclusive of depreciation and amortization.
All significant intercompany transactions are eliminated in consolidation.
The results of operations for the three and nine months ended September 30, 2021, are not indicative of the results to be expected for the full fiscal year ending December 31, 2021. The condensed balance sheet at December 31, 2020, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. In the opinion of management, all adjustments (consisting of only normal and recurring adjustments) considered necessary for a fair statement have been included.
Variable Interest Entities
Management evaluates the Company’s ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors.
Privia Physicians join the medical group in their geographic market as an owner of such medical group. Certain of our medical groups are majority-owned by the Company (each, an “Owned Medical Group”), with Privia Physicians owning a minority interest, and some medical groups are owned entirely by Privia Physicians (each, a “Non-Owned Medical Group”). The Company evaluated its relationship with Non-Owned Medical Groups and their historic practice entities (the “Affiliated Practices”) as well as its relationship with Affiliated Practices associated with Owned Medical Groups to determine if any of these entities should be subject to consolidation. The Company does not have ownership interest in any Affiliated Practices; nor does the Company have an ownership in Non-Owned Medical Groups. The Physician Member Services Agreement (“PMSA”) and Support Services Agreement (“SSA”) entered by Non-Owned Medical Groups with their Privia Physician members and the Affiliated Practices are not contractual relationships within Privia’s legal structure. The only contractual relationship between Privia and Non-Owned Medical Groups is established through the MSA. Management has determined, based on the provisions of the MSAs between the Company and Non-Owned Medical Groups, and after considering the requirements of Accounting Standards Codification (“ASC”) Topic 810,
6

Table of Contents
Consolidation (“ASC 810”), the Company is not required to consolidate the financial position or results of operations of the Affiliated Practices associated with Owned Medical Groups; nor is it required to consolidate the financial position or results of operations of Non-Owned Medical Groups (and, therefore, the Company is not required to consolidate the Affiliated Practices of the Non-Owned Medical Groups).
Based on the Company’s evaluations, Non-Owned Medical Groups do not represent VIEs. Accordingly, the Company has not consolidated the financial position, results of operations or cash flows of the Non-Owned Medical Groups that are affiliated with the Company by means of a SSA for the nine months ended September 30, 2021 and 2020. Each time the Company enters into a new service agreement or enters into a material amendment to an existing service agreement, the Company considers whether the terms of that agreement or amendment would change the elements it considers in accordance with the VIE guidance. The same analysis was performed for the Affiliated Practices of Owned Medical Groups, which have contractual relationships with Privia through SSAs, and the Company determined they do not represent VIEs as they do not meet the criteria in ASC 810.
Emerging Growth Company Status
We are an emerging growth company under the Jumpstart Our Business Startups Act (the “JOBS Act”). The JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company”, we choose to rely on such exemptions, we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Sarbanes-Oxley Act of 2002, Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board (“PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) hold non-binding advisory votes on executive compensation and obtain shareholder approval of any golden parachute payments not previously approved. These exemptions will apply for a period of five years following the completion of our IPO or until we are no longer an “emerging growth company,” whichever is earlier.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure. On an on-going basis we evaluate significant estimates and assumptions, including, but not limited to, revenue recognition, stock-based compensation, estimated useful lives of assets, intangible assets subject to amortization, and the computation of income taxes. Future events and their effects cannot be predicted with certainty; accordingly, the Company’s accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of the financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company’s operating environment changes. Management evaluates and updates assumptions and estimates on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.
Operating Segments
The Company determined in accordance with ASC 280, Segment Reporting (“ASC 280”) that the Company operates in and reports as a single operating segment, and therefore one reporting segment – Privia Health Group, Inc. Refer to Note 14 “Segment Financial Information” for additional information concerning the Company’s services.

7

Table of Contents
Coronavirus Aid, Relief and Economic Stimulus Act (“CARES Act”)
The current COVID-19 pandemic had an impact on our results of operations, cash flow and financial position for the three and nine months ended and as of September 30, 2021 and 2020, as we experienced lower volumes than anticipated and shifts in the mix of services provided after the onset of the pandemic in the United States. See the Prospectus for additional information on impacts during 2020. We are closely monitoring the impact of the pandemic on all aspects of our business including impacts to employees, customers, patients, suppliers and vendors.

On March 27, 2020, the CARES Act was passed. It is intended to provide economic relief to individuals and businesses affected by the coronavirus pandemic. It also contains provisions related to healthcare providers’ operations and the issues caused by the coronavirus pandemic. The following are significant economic impacts for the Company and its subsidiaries as a result of specific provisions of the CARES Act for the three and nine month periods ended September 30, 2021:
The Company elected to defer its portion of Social Security taxes in 2020, which may be repaid over two years as follows: 50% by the end of 2021 and 50% by the end of 2022. Approximately $1.6 million is recorded in accrued expenses on the balance sheet as of September 30, 2021 related to this deferral and the Company intends to remit payment by the end of 2021; and
The Company received $13.3 million in grant funds from the Provider Relief Fund under the CARES Act during the nine months ended September 30, 2020. No funds were received from the Provider Relief Fund under the CARES Act during the nine months ended September 30, 2021.
Non-Controlling Interest
The non-controlling interest represents the equity interest of the non-controlling equity holders in results of operations of Complete MD Solutions LLC, Privia Management Services Organization (“PMSO”) and our Owned Medical Groups. The condensed consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates where the Company has a controlling financial interest. The Company has separately reflected net income attributable to the non-controlling interests in net income in the condensed consolidated statements of operations.
Significant Accounting Policies
The Company described its significant accounting policies in Note 1 of the notes to condensed consolidated financial statements for the year ended December 31, 2020 in the Prospectus. During the three and nine months ended September 30, 2021, there were no significant changes to those accounting policies, other than those policies impacted by the new accounting pronouncements adopted during the period noted below and further described below in “Recently Adopted Accounting Pronouncements.”
Leases
Beginning January 1, 2021, the Company accounts for its leases in accordance with ASU 2016-2, Leases (Topic 842). The Company evaluates whether a contract is or contains a lease at the inception of the contract. Upon lease commencement, which is defined as the date on which a lessor makes the underlying asset available to the Company for use, the Company classifies the lease as either an operating or finance lease. The Company’s leases primarily consist of operating leases for office space in certain states in which we operate. The Company also has operating leases for equipment, which are not significant.
Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are measured at the present value of the remaining, fixed lease payments at lease commencement. The Company uses its incremental borrowing rate, adjusted for the effects of collateralization, based on the information available at the later of adoption, inception, or modification in determining the present value of lease payments. Right-of-use assets are measured at an amount equal to the initial lease liability, plus any prepaid lease payments (less any incentives received) and initial direct costs, at the lease commencement date. The Company has elected to account for lease and non-lease components as a single lease component for its facility leases. As a result, the fixed payments that would otherwise be allocated to the non-lease components are accounted for as lease payments and are included in the measurement of the Company’s right-of-use asset and lease liability. Lease expense for lease payments is recognized on a straight-line basis over the lease term in general and administrative expense on the condensed consolidated statements of operations.
The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. When determining whether a lease qualifies as a short-term lease, the Company evaluates the lease term and the purchase option in the same manner as all other leases.
8

Table of Contents
Recently Adopted Accounting Pronouncements
The Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), as of January 1, 2021 using the modified retrospective transition approach for leases which existed on that date. Prior comparative periods were not adjusted and continue to be reported in accordance with Accounting Standards Codification (“ASC”) Topic 840, Leases. The Company elected the package of practical expedients that permitted the Company not to reassess the Company’s prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. The adoption of the standard resulted in the recognition of operating right-of-use assets of approximately $6.0 million and operating lease liabilities of approximately $11.3 million. Refer to Note 4 “Leases” for additional details. The difference between the operating lease right-of-use assets and operating lease liabilities resulted from the reclassification of deferred rent. Adoption of the standard did not have a material impact on the consolidated statements of operations or cash flows for the three months and nine months ended September 30, 2021. The Company did not recognize a cumulative-effect adjustment to retained earnings upon adoption.
On January 1, 2021, the Company adopted ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“CECL”), which replaces the incurred loss approach for recognizing credit losses on financial instruments with an expected loss approach. The expected loss approach is subject to management judgments using assessments of incurred credit losses, assessments of current conditions, and forecasts using reasonable and supportable assumptions. The Company adopted the standard using a modified retrospective approach which resulted in no adjustments to the allowance for credit losses and no cumulative-effect adjustment to retained earnings. The Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including historical losses adjusted for current market conditions, the Company's customers' financial condition, delinquency trends, aging behaviors of receivables and credit and liquidity indicators for industry groups, and future market and economic conditions. As of September 30, 2021, the allowance for credit losses was not material.
Recently Issued Accounting Pronouncements Pending Adoption
In March 2020, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 eliminates certain exceptions related to the approach for intra period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance is effective for the Company for the year ending December 31, 2022. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2019-12 on its condensed consolidated financial statements.
In March 2020, FASB issued ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides temporary relief from some of the existing rules governing contract modifications when the modification is related to the replacement of the London Interbank Offered Rate (“LIBOR”) or other reference rates discontinued as a result of reference rate reform. The ASU specifically provides optional practical expedients for contract modification accounting related to contracts subject to ASC 310, Receivables, ASC 470, Debt, ASC 842, Leases, and ASC 815, Derivatives and Hedging. The ASU also establishes a general contract modification principle that entities can apply in other areas that may be affected by reference rate reform and certain elective hedge accounting expedients. For eligible contract modifications, the principle generally allows an entity to account for and present modifications as an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. That is, the modified contract is accounted for as a continuation of the existing contract. The standard was effective upon issuance on March 12, 2020, and the optional practical expedients can generally be applied to contract modifications made and hedging relationships entered into on or before December 31, 2022. Borrowings under the Company’s Credit Facilities bear interest based on LIBOR or an alternate rate. Provisions currently provide the Company with the ability to replace LIBOR with a different reference rate in the event that LIBOR ceases to exist.

9

Table of Contents
2. Revenue Recognition

The following table presents our revenues disaggregated by source:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(Dollars in Thousands)2021202020212020
FFS-patient care $200,208 $168,622 $550,607 $474,816 
FFS-administrative services 16,407 14,489 47,162 42,663 
Shared savings 25,333 15,905 62,045 49,441 
Care management fees (PMPM) 9,376 7,024 27,321 20,320 
Other revenue 200 1,130 3,752 16,136 
Total Revenue $251,524 $207,170 $690,887 $603,376 

Fee-for-service (“FFS”) patient care is primarily generated from third-party payers with which the Company has established contractual billing arrangements. The following table presents the approximate percentages by source of net operating revenue received for healthcare services we provided for the periods indicated:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2021202020212020
Commercial insurers 70 %69 %69 %68 %
Government payers 17 %18 %16 %16 %
Patient 13 %13 %15 %16 %
100 %100 %100 %100 %
FFS-administrative services revenue is earned through the Company’s MSA with Non-Owned Medical Groups primarily based on a fixed percentage of net collections on patient care generated by those medical groups.
Value Based Care (“VBC”) revenue is generated through per member per month Care management fee (“PMPM”) payments, from payers to provide care coordination services to patients and through shared savings contracts with large commercial payer organizations and the U.S. Federal Government.
Contract Asset
The Company has the following contract assets and unearned revenue:
(Dollars in Thousands)September 30, 2021December 31, 2020
Balances for contracts with customers
Accounts receivable $98,384 $99,118 
Unearned revenue $4,832 $2,759 
Unearned Revenue
Unearned revenue is presented on the condensed consolidated balance sheet under other current liabilities and represent payments made to, or due from, customers in advance of our performance. All contracts are less than or equal to twelve months. Changes in the balance of total deferred revenue during the nine months ended September 30, 2021 are as follows:
(Dollars in Thousands)December 31, 2020Additions Revenue
Recognized
September 30, 2021
Unearned revenue $2,759 3,161 (1,088)$4,832 
During the three and nine months ended September 30, 2021, the Company recognized approximately $0.2 million and $1.1 million, respectively, of revenue related to amounts unearned as of December 31, 2020.
10

Table of Contents
Remaining Performance Obligations
As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to continue receiving services at our facilities.

3. Goodwill and Intangible Assets, Net
For the purposes of the goodwill impairment assessment, the Company as a whole is considered to be the reporting unit. The fair value of the reporting unit is estimated using a combination of three approaches, all equally weighted: a) discounted cash flow analysis (income approach), b) fair value of comparable transactions (transaction approach) and c) enterprise value to revenue multiple for comparable companies (market approach). Potential impairment is indicated when the carrying value of a reporting unit exceeds its estimated fair value. The Company’s carrying value of goodwill at September 30, 2021 and December 31, 2020 is approximately $118.7 million. The most recently completed annual impairment test of goodwill was performed as of October 1, 2020 and the fair value of the reporting unit exceeded the carrying value and therefore it was determined that no impairment existed. No indicators of impairment were identified during the nine months ended September 30, 2021 and 2020.
A summary of the Company’s intangible assets is as follows:
September 30, 2021December 31, 2020
(Dollars in thousands)Intangible
Assets
Accumulated
Amortization
Intangible
Assets
Accumulated
Amortization
Trade names $4,600 $1,629 $4,600 $1,457 
Consumer customer relationships 2,500 1,771 2,500 1,583 
PMG customer relationships 600 177 600 158 
Management Service Agreement (Complete MD) 2,200 825 2,200 722 
9,900 $4,402 9,900 $3,920 
Less accumulated amortization (4,402)(3,920)
Intangible assets, net $5,498 $5,980 
The remaining weighted average life of all amortizable intangible assets is approximately 10 years at September 30, 2021.
Amortization expense for intangible assets was approximately $0.2 million for both the three months ended September 30, 2021 and 2020, respectively, and $0.5 million for both the nine months ended September 30, 2021 and 2020, respectively.
Estimated amortization expense for the Company’s intangible assets for the following five years is as follows:
(Dollars in Thousands)
Remainder of 2021$160 
2022643 
2023643 
2024559 
2025393 
Thereafter3,100 
Total$5,498 


11

Table of Contents
4. Leases

The Company leases office space under various operating lease agreements. The initial terms of these leases range from 2 to 7 years and generally provide for periodic rent increases and renewal options.

The components of lease expense were as follows (in thousands):

(Dollars in Thousands)For the Three Months Ended September 30, 2021For the Nine Months Ended September 30, 2021
Operating lease cost$475 $1,406
Cash paid for amounts included in the measurement of lease liabilities - operating leases$1,629
Weighted-average remaining lease term - operating leases4.8 Years
Weighted-average discount rate - operating leases3.5 %


The aggregate future lease payments for operating leases in the years subsequent to September 30, 2021 are as follows:

(Dollars in Thousands)
Remainder of 2021$549 
20222,213 
20232,261 
20242,274 
20252,237 
Thereafter1,407 
Total future lease payments10,941 
Imputed interest(901)
Total$10,040 

5.Property and Equipment, Net
A summary of the Company’s property and equipment, net is as follows:
(Dollars in Thousands)September 30, 2021December 31, 2020
Furniture and fixtures $1,110 $1,073 
Computer equipment 1,430 1,051 
Leasehold improvements 4,827 4,863 
7,367 6,987 
Less accumulated depreciation and amortization (3,026)(2,173)
Property and equipment, net $4,341 $4,814 
6.Accrued Expenses
Accrued expenses consisted of the following:
(Dollars in Thousands)September 30, 2021December 31, 2020
Accrued employee compensation and benefits $5,587 $6,167 
Bonuses payable 7,903 10,418 
Other accrued expenses 17,813 14,600 
Total accrued expenses $31,303 $31,185 

12

Table of Contents
7. Note Payable
The Company’s Credit Facilities consists of the following:
(Dollars in Thousands)September 30, 2021December 31, 2020
Note payable $33,469 $34,125 
Less debt issuance costs (930)(466)
Less current portion (875)(875)
Note payable, net $31,664 $32,784 
On November 15, 2019, the Company entered into a Credit Agreement (the “Original Credit Agreement”) by and among Privia Health, LLC, as the borrower, PH Group Holdings Corp., as a guarantor, certain subsidiaries of Privia Health, LLC, as guarantors, Silicon Valley Bank, as administrative agent and collateral agent (the “Administrative Agent”), and the several lenders from time to time party thereto. The Original Credit Agreement provided for up to $35.0 million in term loans (the “Term Loan Facility”) that mature on November 15, 2024 with interest payable monthly at the lesser of LIBOR plus 2.0% or ABR plus 1.0% payable monthly (3.0% at September 30, 2021), plus up to an additional $10.0 million of financing (which was increased to $15.0 million in connection with the first amendment) in the form of a revolving loan (the “Revolving Loan Facility” and together with the Term Loan Facility, the “Credit Facilities”). The Revolving Loan Facility also includes a letter of credit sub-facility in the aggregate availability amount of $2.0 million and a swingline sub-facility in the aggregate availability amount of $2.0 million. The Company borrowed $35.0 million in term loans on November 15, 2019.
On August 27, 2021, the Company and certain of its subsidiaries entered into an assumption agreement and third amendment (the “Third Amendment”) to the Original Credit Agreement (as amended by the Third Amendment, the “Credit Agreement”). Pursuant to the Third Amendment, the Company became the parent guarantor under the Credit Agreement and granted the Administrative Agent a first-priority security interest on substantially all of its real and personal property, subject to permitted liens.
The Third Amendment increased the size of the Revolving Loan Facility to $65.0 million, increased the letter of credit sub-facility to $5.0 million and extended the maturity date of the Credit Agreement to August 27, 2026. As amended, borrowings under the Credit Agreement bear interest at a rate equal to (i) in the case of eurodollar loans, LIBOR plus an applicable margin, subject to a 0.5% floor, and (ii) in the case of ABR loans, an ABR rate plus an applicable margin, subject to a floor of 1.5%. In addition, the Amendment, among other things, (i) changed the Term Loan Facility amortization schedule to 0.625% of the original principal amount of term loans for the fiscal quarters ending September 30, 2021 through and including June 30, 2024 and 1.25% of the original principal amount of term loans for the fiscal quarters ending thereafter and (ii) added a 1.0% prepayment premium for any term loans prepaid within six months of the effective date of the Third Amendment. The Third Amendment converted the financial covenants in the Original Credit Agreement to “springing” financial covenants, so that at any time the Company’s cash is less than 125% of the outstanding borrowings under the Credit Facilities, or at least $15.0 million of borrowings are outstanding under the Revolving Loan, the Company will be required to maintain (i) a consolidated fixed charge coverage ratio of not less than 1.25 to 1.0, and (ii) a consolidated leverage ratio of no more than 3.0 to 1.0. As of September 30, 2021, the Company had $33.5 million in principal amount of indebtedness outstanding under the Term Loan Facility. As of September 30, 2021, “springing” financial covenants were not applicable.
During March 2020, the Company borrowed $10.0 million under the Revolving Loan Facility, which bore interest at the lesser of LIBOR + 2.5% or ABR + 1.5% payable monthly. These borrowings were repaid in 2020 with $5.0 million repaid in July 2020 and $5.0 million repaid in September 2020. On August 30, 2021, the Company increased its capacity under the Revolving Loan Facility from $15.0 million to $65.0 million. As of September 30, 2021 and December 31, 2020 there were no amounts outstanding under the Revolving Loan Facility.
Interest expense relating to the Credit Facilities was approximately $0.3 million and $0.5 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $1.5 million for the nine months ended September 30, 2021, and 2020, respectively.
Debt issuance costs relating to the Credit Facilities of approximately $0.9 million have been capitalized and are being amortized over the life of the Credit Facilities using the effective interest method. Amortization expense of approximately $0.1 million was recorded for both the nine months ended September 30, 2021 and 2020, respectively, and a de minimis amount for both the three months ended September 30, 2021 and 2020, respectively.
Substantially all of the Company’s real and personal property serve as collateral under the above debt arrangements.

13

Table of Contents
Annual aggregate principal payments applicable to the note payable for years subsequent to September 30, 2021 are as follows:
(Dollars in Thousands)
Remainder of 2021$219 
2022875 
2023875 
20241,313 
20251,750 
Thereafter28,437 
Total$33,469 
8. Income Taxes
The Company recorded an income tax benefit of $2.2 million and $8.6 million for the three months ended September 30, 2021 and 2020, respectively, and a income tax benefit of $20.2 million and $7.4 million for the nine months ended September 30, 2021 and 2020, respectively. This represents an estimated annual effective tax rate of 9.7% and 1.0% as of September 30, 2021 and 2020, respectively. The effective tax rate for the three and nine month periods ended September 30, 2021 was lower than the statutory rate due to the effect on the pre-tax loss of the non-deductible stock-based compensation expense related to the Company’s IPO. The effective tax rate for the three and nine month periods ended September 30, 2020 was lower than the statutory rate due primarily to the reversal of the allowance on the deferred tax asset. Additionally, the benefit for the 3 months ended September 30, 2020 is higher than the nine months ended September 30, 2020 due to the release of the valuation allowance in the third quarter of 2020 as that is the period that the weight of all available positive evidence outweighed the weight of the negative evidence when evaluating the ability for the deferred tax asset to be realized in the future. Prior to the third quarter in 2020, tax expense was realized as a result of the increase in the deferred tax liability with all other deferred tax balances offset by the full valuation allowance recorded.

We consider both positive and negative evidence when evaluating the recoverability of our DTAs. The assessment is required to determine whether, based on all available evidence, it is more likely than not (i.e., greater than a 50% probability) that all or some portion of the DTAs will be realized in the future. As of September 30, 2021 and 2020, the weight of all available positive evidence was greater than the weight of all negative evidence, so a valuation allowance against the deferred tax asset was not recorded.
9. Stockholders’ Equity
Anthem Private Placement
On May 3, 2021, concurrent with the closing of its IPO, the Company issued and sold, 4,000,000 shares of common stock, par value $0.01 per share, of the Company for an aggregate purchase price of $92 million (the “Private Placement”), or $23.00 per share, in a private placement to an affiliate of Anthem. As of May 3, 2021, Anthem holds approximately 3.9% of the issued and outstanding common stock of the Company. The securities issued to the Investor in the Private Placement were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933.
Stock option plan
The PH Group Holdings Corp. Stock Option Plan (the PH Group Option Plan) was created on January 17, 2014. The employees of the Company and its subsidiaries, consultants of the Company and the employees of Brighton Health Plan Services Holdings Corp. (BHPS) (a wholly-owned subsidiary of BHG Holdings) and its subsidiaries who have performed services for the Company were the participants of the PH Group Option Plan. The aggregate number of shares of common stock for which options may be granted under the PH Group Option Plan shall not exceed 4,229,850 shares.
Effective August 11, 2016, the PH Group Option Plan was transferred to its parent and became the PH Group Parent Corp. Stock Option Plan (the “PH Parent Option Plan” or “Prior Plan”). All other terms in the PH Group Option Plan remained unchanged in the PH Parent Option Plan at the effective date of the transfer.
Effective August 28, 2018, the PH Parent Option Plan was amended and restated to increase the aggregate number of shares of common stock for which options may be granted from 4,229,850 shares to 18,985,846 shares.
On April 1, 2021, contingent on the consummation of the IPO, the Board of Directors approved a modification to the PH Group Parent Corp. Stock Option Plan of the vesting conditions of certain outstanding stock option grants to certain employees and consultants. The modification accelerated by one year any time vested options that were not previously 100% vested and modified the vesting condition of the performance based options to vest 60% at IPO, 20% 12 months after IPO and 20% 18 months after the IPO. The modification also accelerated the CEO’s time based options by an additional four months such that 100% of his time based options are vested. We recognized stock-based compensation of $195.1 million in the second quarter of 2021 related to these modifications and we expect to
14

Table of Contents
recognize an additional $89.9 million of additional stock compensation expense over the eighteen months following the completion of the IPO.

2021 Omnibus Incentive Plan

On April 6, 2021, the Company approved the Privia Health Group, Inc. 2021 Omnibus Incentive Plan (the “Plan”) which permits awards up to 10,278,581 shares of the Company’s common stock. The Plan also allows for an automatic increase on the first day of each fiscal year following the effective date of the Plan by an amount equal to the lesser of (i) 5% of outstanding shares on December 31 of the immediately preceding fiscal year or (ii) such number of shares as determined by the Company’s Compensation Committee in its discretion. The Plan provides for the granting of stock options at a price equal to at least 100% of the fair market value of the Company’s common stock as of the date of grant. The Plan also provides for the granting of Stock Appreciation Rights, Restricted Stock, Restricted Stock Units (“RSUs”), Performance Awards and other cash-based or other stock-based awards, all which must be granted at not less than the fair market value of the Company’s common stock as of the date of grant. Participants in the Plan may include employees, consultants, other service providers and non-employee directors. On the effective date of the IPO, the Company issued 1,183,871 restricted stock units at the offering price and 3,683,217 options, with an exercise price equal to the offering price. These issuances are expected to generate stock-based compensation expense of $62.3 million to be recognized over the next four years starting on the effective date of the IPO as both the restricted stock units and stock options vest. The 2021 Plan is intended as the successor to and continuation of the PH Parent Option Plan. No additional stock awards will be granted under the Prior Plan.
2021 Employee Stock Purchase Plan
In April 2021, the Company’s Board of Directors approved the Company’s 2021 Employee Stock Purchase Plan (“2021 ESPP”). The 2021 ESPP became effective upon the execution of the underwriting agreement for the Company’s IPO in April 2021. Per the Plan, shares may be newly issued shares, treasury shares or shares acquired on the open market. The Compensation Committee may elect to increase the total number of Shares available for purchase under the Plan as of the first day of each Company fiscal year following the Effective Date in an amount equal to up to one percent (1%) of the shares issued and outstanding on the immediately preceding December 31; provided that the maximum number of shares that may be issued under the Plan in any event shall be 10,278,581 shares. As of the IPO, the Company has reserved 1,027,858 shares of common stock for issuance under the 2021 ESPP.
Stock option activity
The following table summarizes stock option activity under the Prior Plan and Plan:
Number of SharesWeighted-
Average
 Exercise Price
Weighted-
Average
Grant-Date
 Fair Value
Weighted-
Average
Remaining
Contractual
Life
Balance at December 31, 202018,300,959 $2.01 $0.34 7.82
Granted3,730,717 23.16 9.58 
Exercised(328,323)2.11 0.48 
Forfeited(172,547)9.73 3.75 
Balance at September 30, 202121,530,806 $5.61 $1.91 7.51
Exercisable at September 30, 202112,272,394 $2.01 $0.34 7.01
RSU Activity

The following table summarizes the RSU activity under the 2021 Plan:
Number of SharesGrant Date Fair Value
Unvested and outstanding at December 31, 2020 $ 
Granted1,199,315 23.19 
Vested(195,652)23.00 
Forfeited(14,011)23.00 
Unvested and outstanding at September 30, 2021989,652 $23.23 

15

Table of Contents
Stock-based compensation expense
Total stock-based compensation expense for the three months ended September 30, 2021 and 2020, was approximately $25.8 million and $0.1 million, respectively, and $228.5 million and $0.4 million for the nine months ended September 30, 2021 and 2020, respectively. At September 30, 2021, there was approximately $119.1 million of unrecognized stock-based compensation expense related to unvested options and RSUs, net of forfeitures, that is expected to be recognized over a weighted-average period of 1.0 year.
Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(Dollars in Thousands)2021202020212020
Cost of platform$4,947 $ $40,987 $ 
Sales and marketing1,028  8,723  
General and administrative19,825 121 178,751 363 
Total stock-based compensation$25,800 $121 $228,461 $363 
10. Related-Party Transactions
On October 31, 2020, $4.0 million of related party receivables was used to repay $4.0 million of the Notes payable to related parties, leaving $4.7 million of Notes payable to related parties. The Company paid interest of $0.2 million through October 31, 2020. In addition, on December 22, 2020, the remaining $4.7 million of Notes payable to related parties were converted to a capital contribution, leaving no remaining Notes payable to related parties outstanding as of December 31, 2020.
11. Commitments and Contingencies
There are no material commitments and contingencies as of September 30, 2021.
12. Concentrations of Credit Risk
Our financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. While our cash and cash equivalents are managed by reputable financial institutions, the Company’s cash balances with the individual institutions may at times exceed the federally insured limits. At September 30, 2021, substantially all of the Company’s cash and cash equivalents were held at two financial institutions. The Company believes these financial institutions are financially sound and that minimal credit risk exists.
The Company receives payment for medical services provided to patients by its physicians through contracts with payers. Six payers within the network accounted for approximately 84% and 85% of such payments for the three month periods ended September 30, 2021 and 2020, respectively, and 82% for both the nine month periods ended September 30, 2021 and 2020, respectively. The Company evaluates accounts receivable to determine if they will ultimately be collected. In performing this evaluation, significant judgments and estimates are involved, such as past experience, credit quality, age of the receivable balance and current economic conditions that may affect ability to pay. As of September 30, 2021 and December 31, 2020, the Company had six payers within the network that made up approximately 71% and 70% of accounts receivable, respectively.
13. Net (Loss) Income Per Share
A reconciliation of net (loss) income available to common shareholders and the number of shares in the calculation of basic and diluted earnings (loss) income per share was calculated as follows:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(in thousands, except for share and per share amounts)2021202020212020
Net (loss) income attributable to Privia Health Group, Inc. common stockholders $(9,115)$16,685 $(176,251)$27,380 
Weighted average common shares outstanding - basic and diluted 105,896,622 95,950,929 101,576,775 95,945,804 
Earnings per share attributable to Privia Health Group, Inc. common stockholders – basic and diluted$(0.09)$0.17 $(1.74)$0.29 

16

Table of Contents
The treasury stock method is used to consider the effect of the potentially dilutive stock options. The following weighted-average outstanding shares of potentially dilutive securities were excluded from computation of diluted loss per share attributable to common shareholders for the period presented because including them would have been antidilutive:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2021202020212020
Potentially dilutive stock options and RSUs to purchase common shares 20,352,659 17,952,492 20,410,709 17,977,529 
Total potentially dilutive shares 20,352,659 17,952,492 20,410,709 17,977,529 
14.Segment Financial Information
The Company determined in accordance with ASC Topic 280, Segment Reporting (“ASC 280”), that the Company operates in and reports as a single operating segment, which is to care for its patients’ needs. Operating segments are identified as components of an enterprise where separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, who reviews financial operating results on a regular basis for the purpose of allocating resources and evaluating financial performance.
The Company defines its CODM as its Chief Executive Officer, who regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. Although the Company derives its revenues from a number of different geographic regions, the Company neither allocates resources based on the operating results from the individual regions, nor manages each individual region as a separate business unit. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability. As of September 30, 2021 and December 31, 2020, all of the Company’s long-lived assets were located in the United States and for the three and nine months ended September 30, 2021 and 2020 all revenue was earned in the United States.

17

Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes included elsewhere in this quarterly report on Form 10-Q. In addition, the following discussion and analysis and information contains forward-looking statements about the business, operations and financial performance of the Company based on our current expectations that involve risks, uncertainties and assumptions. Our actual results could differ materially from those anticipated by these forward-looking statements as a result of many factors. including, but not limited to, those identified below and those discussed in the sections titled “Risk Factors” and “Information Regarding Forward-Looking Statements” in this quarterly report on Form 10-Q.
Overview
Privia Health is a technology-driven, national physician-enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings on the “Privia Platform”. We directly address three of the most pressing issues facing physicians today: the transition to the VBC reimbursement model, the ever-increasing administrative requirements to operate a successful medical practice and the need to engage patients using modern user-friendly technology. We seek to accomplish these objectives by entering markets and organizing existing physicians and non-physician clinicians into a unique practice model that combines the advantages of a partnership in a large regional Medical Group with significant local autonomy for Privia Providers joining our Medical Groups. Our Medical Groups are designated as in-network by all major health insurance plans in all of our markets and all Privia Providers are credentialed with such health insurance plans.
Our platform is purpose-built, organizing physicians into cost efficient, value-based and primary-care centric networks bolstered by strong physician governance, and promotes a culture of physician leadership. The Privia Platform is powered by the Privia Technology Solution, which efficiently manages all aspects of our Privia Physicians’ provision of healthcare services and eliminates the complexity and reduces the cost of otherwise having to buy more than 30 point solutions. We enhance the patient experience, improve practice economics and influence point of care delivery through investments in data analytics, revenue cycle management (“RCM”), practice and clinical operations and payer alignment. The Privia Platform is designed to succeed across demographic cohorts, acuity levels and reimbursement models, including traditional FFS Medicare, Medicare Shared Savings Program (“MSSP”), Medicare Advantage, Medicaid, commercial insurance and other existing and emerging direct contracting programs with payers and employers. We believe that the Privia model is a highly scalable solution to help our nation’s healthcare system achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers. Our customers have affirmed our model, as Privia has rapidly become one of the nation’s leading independent physician companies since launching our first Medical Group in 2013.
There are three core elements to our physician alignment approach:
1)A focus on maximizing the potential of a physician’s medical practice across the physician’s entire patient panel, with the end goal of succeeding in VBC reimbursement;
2)A highly flexible payer-agnostic approach to address the needs of multiple types of physician practices, from independently owned to hospital employed or hospital affiliated practices; and
3)Delivering a profitable model for both Privia and our Privia Physicians, regardless of the reimbursement model, geographic environment or specialty.
The Privia Platform is powered by the Privia Technology Solution, which efficiently manages all aspects of our Privia Physicians’ practices and eliminates the complexity and reduces costs. The intended result is engaged physicians and non-physician clinicians delivering high quality virtual and in-person healthcare to patients with superior clinical outcomes and experiences at lower costs. We believe our technology-enabled platform is highly scalable, allowing us to both rapidly build density in new g